Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Common grade 3 or 4 side effects with sorafenib include lymphopenia (13%), hypophosphatemia (13%), elevated lipase (12%), hand-foot syndrome (6%), and mucositis/ stomatitis (6%). Common grade 3 or 4 side effects with suntinib elevated lipase (16%), neutropenia (12%), lymphopenia (12%), hypertension (8%), and fatigue/ asthenia (7%). As for temsirolimus, common grade 3 or 4 side effects consist of anemia (20%), hyperglycemia (11%), fatigue/ asthenia (11%), dyspnea (9%), and hypophosphatemia (5%). Intracranial hemorrhage (ICH) is rare but occurred in sorafenib-exposed and sunitinb-exposed patients. Cardiovascular morbidity may also be observed in sorafenib-exposed and sunitinib-exposed patients. SUMMARY: Through preventive and therapeutic measures, these side effects can be effectively managed, without reducing the dose and, therefore, affecting the efficacy of the treatment.
|
Authors | Catherine Guevremont, Ahmed Alasker, Pierre I Karakiewicz |
Journal | Current opinion in supportive and palliative care
(Curr Opin Support Palliat Care)
Vol. 3
Issue 3
Pg. 170-9
(Sep 2009)
ISSN: 1751-4266 [Electronic] United States |
PMID | 19528803
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Benzenesulfonates
- Indoles
- Phenylurea Compounds
- Pyridines
- Pyrroles
- Niacinamide
- temsirolimus
- Sorafenib
- Protein-Tyrosine Kinases
- Sunitinib
- Sirolimus
|
Topics |
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Benzenesulfonates
(adverse effects, therapeutic use)
- Carcinoma, Renal Cell
(drug therapy, secondary)
- Clinical Trials as Topic
- Drug-Related Side Effects and Adverse Reactions
(prevention & control, therapy)
- Humans
- Indoles
(adverse effects, therapeutic use)
- Kidney Neoplasms
(drug therapy, pathology)
- Niacinamide
(analogs & derivatives)
- Phenylurea Compounds
- Practice Guidelines as Topic
- Protein-Tyrosine Kinases
(adverse effects, therapeutic use)
- Pyridines
(adverse effects, therapeutic use)
- Pyrroles
(adverse effects, therapeutic use)
- Sirolimus
(adverse effects, analogs & derivatives, therapeutic use)
- Sorafenib
- Sunitinib
|